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Head and neck squamous cell carcinoma (HNSCC) is the 6
th
 most common type of 
cancer in the western hemisphere with a five-year survival rate of only 50% for patients 
with a localized tumor, which decreases significantly to as low as 5% for those patients 
with tumors that have metastasized to distant sites of the body. It has been found that both 
mutant p53 and epidermal growth factor receptor (EGFR) signaling pathways function to 
increase the expression of CXCL5, which has been identified as a key mediator in the 
process of tumor metastasis. Previous data from our lab suggested that the p53 homolog, 
p63, may function as a negative regulator of CXCL5 and that mutant p53 may inhibit this 
molecule to elevate CXCL5 expression levels. 
   
 xi 
In the current study we utilized an model system in which the H179L p53 mutant 
was expressed in HN4 cells to investigate the hypothesis that mutant p53 enhances 
expression of CXCL5 by both interfering with p63 function and cooperating with 
EGFR/EPS8 signaling, leading to increased cell proliferation and motility. The results of 
the current study indicate a role for mutant p53 in head and neck squamous cell carcinoma 
proliferation, migration and tumorigenicity, possibly through enhancement of CXCL5 
expression. We were able to show that mutant p53 expression caused an increase in the 
expression of this chemokine in addition to increasing proliferation and migration of the 
cells compared to the vector control. Additionally, we showed that p63 protein is a 
negative regulator of CXCL5 that is downregulated in the cells expressing mutant p53, 
which suggests that through direct interaction, mutant p53 may function to inhibit p63 
function as well as target it for degradation. These results support the hypothesis that GOF 
mutant p53 enhances expression of CXCL5 by interfering with p63 function in cancer 
cells. The results of the current study results also showed that upon treatment with EGF, 
HN4 cells expressing mutant p53 express elevated levels of CXCL5; and that the mutant 
p53-expressing HN4 cells cooperate with EGFR/EPS8 signaling to further deregulate 
chemokine expression. These data taken together suggest there are complex interactions 
taking place between mutant p53, p63, EGFR signaling, and CXCL5 to regulate the 
biological processes that promote tumor progression that could lead to metastasis. 
Additional studies are needed to further elucidate the molecules involved in the mutant p53 
mechanism that promotes tumorigenesis. 
 
  1 
 
Introduction and Background 
 
 
 
1.1 Head and Neck Squamous Cell Carcinoma (HNSCC) 
Head and neck squamous cell carcinoma (HNSCC) is the name given to cancers 
that begin in the mucosal lining epithelial cells of the upper aerodigestive tract (1), which 
includes cells of the oral cavity, tongue, pharynx, larynx, and paranasal sinuses (2). 
HNSCC is the 6
th
 most common type of cancer in the western hemisphere with a five-year 
survival rate of 50% for patients with a localized tumor (2). Death typically occurs as a 
result of uncontrolled disease progression, both because of recurring local primary tumor 
and because of metastasis to distant sites in the body (1). Metastasis is the major reason for 
poor survival rates that drop as low as 5% despite continued efforts to improve treatments 
(3). 
Two risk factors that have been identified as causes of head and neck squamous cell 
carcinoma are tobacco and alcohol use (4, 5) with tobacco use being the main contributor. 
The carcinogens present in tobacco smoke have genotoxic effects on the head and neck 
epithelial cells, which can lead to mutations that can result in tumor formation. In 
particular, there is a link between tobacco use and mutations in the p53 tumor suppressor 
gene (6), which can lead to spontaneous tumor formation (7). Alcohol primarily functions 
to synergistically amplify the effects of tobacco use, but its metabolite, acetaldehyde, can 
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also form DNA adducts that can impede DNA repair (8). An additional risk factor in 
HNSCC is human papillomavirus (HPV), which targets basal mucosal epithelial cells and 
transforms them into either a benign form, or high-risk type that can progress to a 
cancerous lesion (4). 
 
1.2 Tumor Metastasis 
Head and neck squamous cell carcinoma is a result of a multi-stage process that 
begins with an accumulation of mutations in normal epithelial cells (9, 10). Mutations 
result in the silencing of tumor suppressors and overexpression (or altered forms) of 
oncogenes (9), allowing for alterations to the normal processes that regulate growth and 
migration, as well as cell differentiation and death (2). 
Accumulation of genetic damage (10) causes normal epithelial cells to progress 
through multiple stages of premalignant lesions and can eventually form a malignancy 
(11). The cells of the primary tumor secrete factors such as VEGF-C that promote their 
growth (12) and cross-talk with the mesenchyme-derived stromal fibroblasts, to further 
increase cell proliferation (2). This interaction between the mesenchyme and the epithelial 
cells results in paracrine activation, which plays a key role in tumorigenesis (13). Secreted 
factors also favor angiogenesis by migration of endothelial cells, and in addition, these 
factors promote the migration of immune cells. The chemokines CXCL5 and CXCL8 have 
been identified as key mediators of this inflammatory component of tumor progression 
(14). As the tumor develops, cells can degrade the extracellular matrix by secreting matrix 
metalloproteases, such as MMP-9 (15) and migrate toward a chemokine gradient (16). This 
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process of metastasis involves the interaction of these primary tumor cells with normal 
epithelial cells, the extracellular matrix, and other associated factors (3). HNSCC 
metastasis usually occurs by tumor cells entering lymph vessels, to be carried to loco-
regional or distant sites in the body (2, 17). The target organs express ligands for receptors 
expressed on the surface of tumor cells, resulting in a “homing mechanism” that favors 
migration (18). The tumor cells that metastasize and colonize a secondary site at a lymph 
node must develop survival mechanisms allowing for the development of a secondary 
lesion (2). 
 
1.3 Chemokines 
Chemokines are a family of small, secreted chemoattractant proteins that are 
classified based on the relationship between conserved cysteine residues (19). The four 
subfamily groups are named CXC, CC, XC, and CX3C, shown in Figure 1. CXC-
chemokines contain two cysteines separated by one residue, CC-chemokines have two 
adjacent cysteine residues, XC-chemokines only have one disulfide bond, and CX3C-
chemokines contain two cysteines separated by three residues. What is unique about 
CX3C-chemokines is that they contain a mucin-like stalk at the C-terminus, which allows 
this molecule to embed into cell membranes, but there is only one known member of this 
subfamily (19). All chemokines have a conserved ‘Greek key’ supersecondary structure 
(shown in Figure 1), which is composed of three connected antiparallel β-strands plus an 
α-helix that is positioned next to the first β-strand, but connected to the third (19). CXC-
chemokines can be further divided based on whether they contain the glutamic acid-
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leucine-arginine (E-L-R) amino acid motif N-terminal to the cysteines. ELR+ CXC-
chemokines, such as CXCL5, typically function as chemoattractants (2) and have been 
linked to the process of tumor formation (14). 
 
 
Figure 1. Chemokine classification by the spacing of conserved cysteines. 
Figure modified according to (19). 
 
1.4 Chemokine Receptors 
Chemokine receptors are members of the G-protein coupled receptor (GPCR) class 
A rhodopsin-like family and are composed of an extracellular domain that includes the N-
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terminus plus 3 loops that work together to bind the chemokine ligand. The intracellular 
domain includes the C-terminus and also contains three loops that transduce the chemokine 
signal (16). Chemokines either bind to a specific GPCR family receptor or activate more 
than one in a promiscuous manner (2). A receptor can also be activated by more than one 
chemokine ligand, as shown in Figure 2. Typically, CXC-chemokines activate CXCR 
receptors and CC-chemokines only activate CCRs (19). 
 
 
Figure 2. Both specific and promiscuous relationships exist between 
chemokine family ligands and receptors. Figure modified according to (2). 
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1.5 CXCL5 Role in HNSCC 
Chemokines normally function in a chemotactic manner to promote the movement 
of pro-inflammatory cells to the site of inflammation by creating a chemokine gradient. 
Chemokines are related to both this normal inflammatory response (17) and to the 
inflammatory component of cancer metastasis in which the chemokine system is 
“hijacked” by tumor cells. Chemokines favor tumor progression by increasing tumor cell 
proliferation and migration (14). Chemokines are also involved with promoting 
angiogenesis (12). 
A specific chemokine of interest is CXCL5, which binds to and activates the 
receptor CXCR2 (2). The expression of chemokines and their receptors is normally a 
tightly-regulated process governed by cytokines and growth factors, but CXCL5 has been 
shown to have increased expression in metastatic cells compared to primary tumor cells. 
This suggests the regulation is altered during tumor progression (18). Previous studies have 
shown that inhibiting the expression of this chemokine can reduce tumor cell migration 
and invasion as well as block tumor formation in vivo (18), which suggests the interaction 
between CXCL5 and CXCR2 is an important mediator in the formation of metastasized 
tumors. Blocking CXCR2 has been identified as a potential therapeutic target to inhibit 
tumorigenesis (2). 
 
1.6 p53 
p53 is a transcription factor and normally functions as a tumor suppressor by 
inducing cell cycle arrest and DNA repair or apoptosis in response to genotoxic cell stress. 
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In this way, p53 prevents proliferation, protects the genome, and eliminates damaged cells 
(7). In over half of all human cancers, however, p53 is mutated or inactivated (7), an event 
that is crucial for the initiation of cancer formation (20). Most of these amino acid 
substitution mutations are found in the DNA-binding domain (Figure 3A) and result in an 
aberrant protein with new gain-of-function oncogenic properties (21). 
Previous studies with lung cancer cells have shown that one of these new functions 
of mutant p53 involves the upregulation of CXCL5 expression as measured by the activity 
of the CXCL5 promoter and transcript levels (20).  Wild-type p53 actually functions to 
repress CXCL5 (20) so a loss of wild-type p53 function is sufficient to induce CXCL5 
expression, while mutant p53 upregulates CXCL5 further (20). 
 
1.7 H179L Mutant p53 
The H179L p53 protein carries a histidine-to-leucine amino acid substitution at 
codon 179, which is located in the DNA-binding domain (21). Previous studies have 
shown that expression of the H179L p53 mutant can transform immortal cells into a 
metastatic phenotype. This shows that a single missense mutation results in a p53 mutant 
that has lost its wild-type function (22) and can act in a dominant negative manner to 
inhibit wild type p53 and possibly other family members (21, 23). 
There are several possible mechanisms by which mutant p53 might enhance 
CXCL5 expression, shown in Figure 3. These include mutant p53 inhibition of its family 
member, p63 (24), direct binding of mutant p53 to the CXCL5 promoter region to activate 
gene expression (20), or activation of NF-κB2 (20) or other transcription factors we have 
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yet to identify. Thus far, GOF mutant p53 has not been demonstrated to bind to the 
CXCL5 promoter. This raises the possibility that additional steps, carried out by other 
proteins, are necessary for regulation of CXCL5.  
 
 
Figure 3. Three of the possible mechanisms by which mutant p53 might 
activate CXCL5 expression. 
 
1.8 p63 
p53 is one member of a family of transcription factors that includes p73 and p63 
(25, 26), the latter of which is highly relevant for the development of stratified epithelial 
tissues, such as the epidermis that functions as a barrier and waterproof seal for the body 
(7). p63 knock-out mice have developmental defects, specifically a lack of any stratified 
squamous epithelium and associated structures such as complex glands. These mice also 
have limb truncations and craniofacial abnormalities, but because of the lack of an 
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epidermis, they do not survive. Together, these observations suggest a crucial functional 
role for p63 in development (7), but p63 also has a distinct role in adulthood, particularly 
in cancer (7). These two different roles played by one molecule are another component 
adding to the controversy surrounding the function of p63 (24). 
Another layer of this controversy is the fact that there are six different p63 
isoforms, arising from two separate promoters plus alternative splicing at the C-terminus, 
shown in Figure 4. All of the isoforms share a common core domain composed of the 
DNA-binding domain (DBD) and oligomerization domain (OD), which have 60% and 
37% homology to the corresponding domains of p53. TA-isoforms arise from the first 
promoter and contain the transactivation domain (TA) that the ΔN-isoforms lack because 
they begin at the second promoter. Additional alternative splicing of the p63 mRNA at the 
C-terminus yields α-, β-, and γ-isoforms. p63α-isoforms contain a sterile alpha motif 
(SAM) that is important in protein-protein interactions and a transactivation inhibitory 
domain (TID) that the shorter p63β- and p63γ-isoforms lack (7, 27). 
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Figure 4. Two promoters plus alternative splicing form six p63 isoforms. 
(A) Functional domains of p53 tumor suppressor. (B) Functional domains of 
p53 homolog, p63. Percentages show identical residues between p53 and p63. 
(C) Two separate promoters and alternative splicing patterns of the p63 mRNA 
transcript to create six individual isoforms. Figure modified according to (7).  
 
The six different p63 isoforms that have distinct structures also have a variety of 
functions, which adds to the complexity of the p63 controversy (24). ΔN-isoforms lack the 
N-terminal transactivation domain and act as dominant inhibitors (28) of TAp63 and wild 
type p53 tumor suppressive function (7, 27). These oncogenic isoforms (22) have been 
shown to inhibit terminal differentiation and promote early tumorigenesis. In both normal 
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epithelial cells and in HNSCC cells, ΔNp63α is the major isoform at the protein level (28). 
ΔNp63 isoforms have also been shown to upregulate the expression of the stem cell marker 
and cell surface glycoprotein, CD44, which is involved in cell migration and adhesion. 
Additionally, p63 activates keratins required for proliferation, while it downregulates other 
keratins to cause a more invasive cell phenotype (29). TA-isoforms are primarily located in 
differentiated cells higher in the epithelium, while ΔN-isoforms are localized to the basal 
epithelial cells and are considered epithelial stem cell markers (24, 29). ΔNp63α has been 
identified in stem cells of the breast and prostate (27). ΔN-isoforms are expressed at the 
barrier between epithelium and mesenchyme, and a loss of p63 has been associated with 
epithelial mesenchymal transition (EMT) in which epithelial cells acquire traits more 
common to mesenchymal cells (3). The mesenchymal phenotype is associated with 
increased metastatic potential (25). Although the different isoforms have been linked to 
certain functions, it isn’t completely clear yet which isoform causes each phenotype. 
Additionally, different cell types express different levels of the p63 isoforms (27). Changes 
in isoform expression are thought to play a role in tumorigenesis by affecting cell 
proliferation and differentiation (27). The large number of targets regulated by p63 (29), 
including transcription factors, adhesion and signaling molecules, and regulatory 
microRNAs (miRNAs) (30), further complicates our understanding of p63 function. 
Unpublished data from our lab show that inhibiting p63 in lung cancer cells results 
in enhanced CXCL5 expression and increased cell motility (W.A. Yeudall, unpublished 
data), which suggests that p63 might act to repress CXCL5 expression. This change in 
CXC-chemokine expression in response to decreased p63 is not observed in normal 
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epithelial cells, suggesting this may be an acquired characteristic of tumor cells (34). 
Additional studies have shown that a loss of p63 results in an increase in the expression of 
genes that favor invasion and metastasis (25, 32), as measured by microarray analysis, and 
that p63 inhibition also causes an increase in squamous carcinoma cell migration (25). A 
loss of p63 has been associated with poor prognosis in some cancers (25). It has also been 
shown that, by interacting with p63, mutant p53 can repress the normal p63 function to 
inhibit metastasis in lung cancer cells (24), which is another reason why we are 
investigating a similar mechanism in an oral cancer cell model. 
 
1.9 Epidermal Growth Factor Receptor (EGFR) Signaling 
Another important aspect of epithelial tumor progression is the epidermal growth 
factor receptor (EGFR) signaling pathway (33). The EGFR is a member of the ErbB family 
of receptor tyrosine kinase and is activated by the binding of EGF-family ligands such as 
EGF and TGF-α (33). Ligands can bind either of two extracellular ligand-binding sites (L1 
and L2 in Figure 4), which induces receptor dimerization with another EGFR via the 
cysteine-rich domains (S1 and S2 in Figure 4). This results in transphosphorylation of 
cytoplasmic tyrosine residues by the intrinsic protein tyrosine kinase activity, which 
promotes docking of SH2-containing proteins to the cytoplasmic domain of the EGFR 
(33). Finally, downstream targets are activated to initiate a biological response (13, 15). 
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Figure 5. Structure of the EGFR monomer. L1 and L2: ligand-binding sites; 
S1 and S2: cysteine-rich domains; SH1: protein tyrosine kinase domain. Figure 
modified according to (13). 
 
This signaling pathway normally functions in differentiation and development, 
migration, apoptosis, and wound healing (13). EGFR signaling enhances motility through 
signal transduction to the actin cytoskeleton, and invasion by promoting the expression of 
matrix metalloproteases that degrade the extracellular matrix (3). Previous studies from our 
lab using microarray analysis have shown that treatment of cells with EGF causes an 
increase in the expression of many genes favoring metastasis, including CXCL5 (18). EGF 
receptors and ligands are often overexpressed in human cancers, allowing for autocrine or 
paracrine cell stimulation, leading to altered gene expression (15). Overexpression of 
EGFR in HNSCC makes it a potential therapeutic target (28).  
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EGFR signaling has also been linked to p63. One study showed that treatment of 
human epithelial cells with EGF resulted in decreased expression of p63 (34), while 
another study with pancreatic ductal adenocarcinoma cells showed that treatment with 
EGF caused an increase in ΔNp63α-induced motility. This same study showed that 
overexpression of ΔNp63α also resulted in EGFR upregulation (10). A third study showed 
decreased p63 expression in HNSCC cells upon treatment with an EGFR inhibitor (28) and 
it has been suggested that in HNSCC, EGF regulates ΔNp63α through the downstream 
mediator, PI3K (7). 
 
1.10 EPS8 Role in HNSCC 
EPS8 is a downstream mediator of the EGFR signaling pathway shown to have 
increased expression in metastasized tumor cells (15). Previous data indicate that EPS8 
upregulates the expression of the FOXM1 transcription factor, resulting in increased 
CXCL5 expression along with increased cell growth and motility (35). It has also been 
shown that inhibition of FOXM1 causes a reduction in CXCL5 expression (35). FOXM1 
has not been localized to the CXCL5 promoter, which raises the possibility that the 
increase in chemokine expression is mediated by other molecules. EPS8 has also been 
shown to be involved with the EGFR-induced upregulation of MMP-9, which is important 
for matrix degradation and processing of both growth factor and cytokine ligands (15). 
Both processes contribute to tumor metastasis and are shown in Figure 6. 
The observed increase in CXCL5 expression seen with activation of the 
EGFR/EPS8 signaling pathway provides rationale for looking at the cooperativity between 
   
 15 
the mutant p53 and EGFR/EPS8 regulation of CXCL5 expression. Our goal is to determine 
whether these pathways independently enhance the expression of this chemokine or if they 
act through the same pathway.  
 
 
Figure 6. EPS8 activates expression of matrix metalloproteases. Figure 
modified according to (15). 
 
1.11 Model System 
For our model system, we chose primary tongue tumor HN4 cells and metastasized 
lymph node HN12 cells, derived from the same patient. These cells were chosen because 
HN4 cells express high levels of p63 and low levels of EPS8 and CXCL5, while HN12 
cells express low levels of p63 (18) and high levels of EPS8 and CXCL5 (3, 18). Previous 
data show that neither of these cell types expresses functional wt-p53 or mutant p53 (21). 
 
 
   
 16 
1.12 Hypothesis and Specific Aims 
In the current study we propose the following hypothesis that GOF mutant p53 
enhances expression of CXCL5 by interfering with p63 function in oral cancer cells, and 
that it cooperates with EGFR/EPS8 signaling to further deregulate chemokine expression, 
leading to increased cell proliferation and motility. We have identified two specific aims to 
investigate this hypothesis. 
Aim 1 involves the investigation of the role of p63 in regulating expression of 
CXCL5. In this aim, we will express p63 in oral cancer cells and determine the effect on 
CXCL5 expression, introduce GOF mutant p53 and p63-specific siRNA into these cells 
and measure CXCL5 by qRT-PCR and ELISA.  
For our second aim, we will investigate the possibility that gain-of-function (GOF) 
mutant p53 cooperates with EGFR signaling to regulate CXCL5. In this aim, we will co-
express EPS8 and mutant p53 in oral cancer cells, and measure CXCL5 mRNA expression. 
We will also determine the response in terms of CXCL5 expression following EGF 
treatment of GOF p53-expressing cells. 
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Figure 7. Hypothesis schematic. 
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Materials and Methods 
 
 
2.1 Cell Cultures 
 HN4 cells derived from a primary tongue squamous cell carcinoma and HN12 cells 
derived from tumor cells that had metastasized to a lymph node from the same patient were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5mL of 
100mM sodium pyruvate (Mediatech, Inc.; Manassas, VA), 5mL of 10,000 U/mL 
penicillin / 10,000 μg/mL streptomycin (Invitrogen; Carlsbad, CA), and 10% fetal bovine 
serum (FBS). 400μg/mL G418-sulfate or 1μg/mL puromycin-2HCl antibiotic (Enzo Life 
Sciences, Inc.; Farmingdale, NY) were added to media for cells to be selected for either 
neomycin or puromycin resistance, respectively. Cells were incubated at 37˚C, 10% CO2 
and the media was changed every 2-3 days. 
 Before cells grew to confluency, the media was aspirated and the plates were 
washed with a phosphate buffered saline (PBS) solution to remove any residual growth 
media. To detatch the cells, 0.1% trypsin-0.88 mM EDTA (Mediatech Inc.; Manassas, VA) 
was added and the plates were incubated at 37˚C for 5-10 minutes. Cells were then 
resuspended in 10mL total volume by addition of complete growth medium and re-plated 
at 1:10 dilution to continue growing. 
 Cell stocks were made by transferring cells to a 15 mL tube following 
trypsinization, and centrifuging the cells for 5 minutes at 4˚C. The media was aspirated off, 
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then cells were resuspended in 1mL of cold Bambanker (Wako Chemicals USA; 
Richmond, VA), and split between two cryo tubes. The stocks were then stored at -80˚C. 
 
2.2 Plasmids and siRNA 
 Complementary DNA sequences cloned into mammalian expression plasmid were 
available in the laboratory. The plasmid containing the ΔNp63α cDNA was obtained from 
the Oral & Pharyngeal Cancer Branch (NIDCR; Bethesda, MD). All plasmids were 
verified by sequencing prior to use. Plasmids used were pcDNAIAmp-p53/H179L, which 
expresses a gain-of-function histidine-to-leucine substitution at codon 179, as described 
previously (21). pcDNA3-mCherry was obtained from Invitrogen (Carlsbad, CA). 
p63 and luciferase siRNAs were synthesized by Sigma-Aldrich, Inc. (St. Louis, MO). 
The target sequences are shown in Table 1. siRNA duplexes were already annealed by the 
supplier. 
 
Gene Target Sequence 
p63(s) 5’- AACAGCCAUGCCCAGUAUGUA[dT][dT]-3’ 
p63(as) 5’-UACAUACUGGGCAUGGCUGUU[dT][dT]-3’ 
Luciferase(s) 5’-CAUGUCAUGUGUCACAUCUC[dT][dT]-3’ 
Luficerase(as) 5’-GAGAUGUGACACAUGACAUG[dT][dT]-3’ 
Table 1. siRNA target sequences 
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2.3 Cell Transfections 
 Cells were nucleofected (Lonza; Allendale, NJ) using electroporation solution 
(Mirius Bio; Madison WI) warmed to room temperature and the T-20 protocol, according 
to the manufacturer’s instructions. 1 x 106 cells per transfection, as determined using a 
Cellometer and Cellometer Auto T4 software (Nexelcom Bioscience, LLC.; Lawrence, 
MA), were resuspended in 100μL electroporation solution and 1μg of the target plasmid 
DNA was added. In some cases, 1μg mCherry plasmid DNA was added to monitor 
transfection efficiency by fluorescence microscopy. After transfer to a cuvette and placing 
the mixture into the Nucleofector II machine (Lonza; Allendale, NJ), the T-20 protocol 
was run. Cells were then placed into a 10cm plate containing 10mL of media that had been 
previously warmed in the incubator. After 48 hours, stable cell lines were selected in the 
presence of either 400μg/mL G418 or 1μg/mL puromycin, depending on the transfected 
DNA plasmid. For transient siRNA transfections, 1μg of target siRNA was used and cells 
were harvested after 48 hours without being grown in selection media. 
 Individual clones from each transfection were isolated by the intensity of 
fluorescence as viewed using a fluorescent microscope and AxioVision software (Carl 
Zeiss Microimaging Inc.; Thornwood, NY). Clones were expanded and target gene 
expression assessed by Western Blot. 
 
2.4 RNA Isolation 
 1mL of TRIzol reagent (Invitrogen; Carlsbad, CA) was added to each well of sub-
confluent cells grown in 6-well plates and incubated on a shaker for 5 minutes at room 
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temperature to homogenize the samples and ensure nucleoprotein complexes were 
dissociated. The contents of each well were transferred to sterile 1.5mL microcentrifuge 
tubes containing 0.2 mL chloroform. Tubes were then shaken vigorously for 15 seconds 
and centrifuged at 12,000 x g for 10 minutes at 4˚C to separate the RNA-containing 
aqueous phase from the phenol phase. The aqueous phase was then removed and 
transferred to a new microcentrifuge tube and RNA was precipitated by adding 0.5mL 
isopropyl alcohol. Tubes were mixed by inverting, and incubated at room temperature for 
10 minutes prior to centrifugation for at 12,000 x g for 10 minutes at 4˚C. The supernatant 
was then removed and the RNA pellet was washed with 1mL 75% ethanol. Again, the 
supernatant was discarded and the pellet dried. RNA was resuspended in 20-30μL RNase-
free water and stored at -20˚C. Precautions were taken with each step to avoid sample 
contamination with RNases to ensure isolation of a pure RNA product. 
 RNA concentration was measured using a spectrophotometer (Nanodrop; 
ThermoScientific; Asheville, NC) and ND1000 software. The purity of isolated RNA was 
assessed by the 260/280 value of each sample, with 260/280 = 2.00 indicating good quality 
RNA. Additionally, 1μg of RNA was electrophoresed in a 1% agarose gel to confirm 
sample purity. 
 
2.5 Reverse Transcription 
 Total RNA was prepared and quantified as previously described, and 1-5μg RNA 
was added to a microfuge tube along with 1μL each of oligo(dT)18 (0.5μg/μL) (Sigma-
Aldrich, Inc.; St. Louis, MO) and dNTP mix (10mM each) (Bioline; Taunton, MA). The 
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volume was made up to 13μL with RNase-free water and the samples were denatured for 5 
minutes at 65˚C. After a quick chill on ice followed by a short centrifugation, 4μL 5X 
First-Strand Buffer (Invitrogen; Carlsbad, CA) and 2μL 0.1M DTT (Invitrogen; Carlsbad, 
CA) were added to each tube. The microfuge tubes were incubated in a 42˚C water bath for 
2 minutes before adding 1μL of MultiScribe reverse transcriptase (50U/μL) (Applied 
Biosystems; Carlsbad, CA) and mixing gently. Samples were then incubated for 50 
minutes at 42˚C to allow the cDNA synthesis reaction to proceed. To inactivate the 
reaction, tubes were heated at 70˚C for 15 minutes. Samples were stored at -20˚C prior to 
use as a template for PCR amplification. 
 
2.6 Polymerase Chain Reaction (PCR) 
 Total RNA was prepared, quantified, and reverse transcribed as previously 
described. The following reagents were added to 200 μL tubes: 5μL 10X PCR Buffer 
minus Mg (Invitrogen; Carlsbad, CA), 1μL 10mM dNTP mixture (10mM each), 1.5μL 
50mM MgCl2 (Invitrogen; Carlsbad, CA), 1μL of 10μM primer mix (see Table 2), 1μL 
template cDNA, and 0.2μL Platinum® Taq DNA Polymerase (Invitrogen; Carlsbad, CA). 
RNase-free water was added to make a final reaction volume of 50μL. Samples were 
mixed and centrifuged briefly before being placed into a GeneAmp PCR System 9700 
thermal cycler (Applied Biosystems; Carlsbad, CA). Tubes were incubated at 94˚C for 2 
minutes to denature the template DNA and activate the DNA polymerase, followed by 35 
PCR amplification cycles: denaturation step at 94˚C for 30 seconds, annealing step at 55˚C 
for 30 seconds, and extension step at 72˚C for 1 minute. The reaction was then held at 4˚C 
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and samples were stored at -20˚C until needed for analysis by agarose gel electrophoresis. 
Oligonucleotide sequences of primers used for PCR were obtained from Sigma-Aldrich, 
Inc. (St. Louis, MO) and are listed in Table 2. 
 
Gene Target Sequence 
p63(s) 5’-GAAACGTACAGGCAACAGCA 
p63(as) 5’-GCTGCTGAGGGTTGATAAGC 
CXCL5(s) 5’-GTGTTGAGAGAGCTGCGTTG 
CXCL5(as) 5’-CTATGGCGAACACTTGCAGA 
γ -tubulin(s) 5’-AGAGGGCTTTGTGCTGTGTC 
γ -tubulin(as) 5’-ACCAGCTTCTTAGGATACCTG 
Table 2. Oligonucleotide sequences for PCR. 
 
2.7 Quantitative Real Time PCR (qRT-PCR) 
 Total RNA was prepared, quantified, and reverse transcribed as previously 
described. The following reagents were added to each well of a fast optical 96-well 
reaction plate (0.1 mL) (Applied Biosystems; Carlsbad, CA): 5μL 2X Blue QPCR SYBR 
low ROX (Thermoscientific; Epsom, Surrey, UK), 3μL RNase-free water, and 1μL of 
primer mix (see Table 2). To reduce the chance of error due to pipetting variability, a 
Master Mix was made containing the previously mentioned reagents for all wells to be 
used and 9μL of the mix was pipetted into each well. 1μL of template DNA was then 
added to triplicate wells. As a negative control with no cDNA template, 1μL of RNase-free 
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water was added to one well per primer mix. 1μL of serial dilutions of previously prepared 
PCR products for each primer combination were also added to wells to generate relative 
standard curves for each gene target. The plate was sealed with an RNase-free optical 
adhesive film (Applied Biosystems; Carlsbad, CA), then centrifuged to collect the samples. 
The plate was then placed into the 7500 Fast Real-Time PCR System thermal cycler 
(Applied Biosystems; Carlsbad, CA) and incubated at 50˚C for 2 minutes then 95˚C for 10 
minutes before cycling through 40 repetitions of 95˚C for 15 minutes and 60˚C for 1 
minute. The amplification cycling was controlled using the 7500 Fast System SDS 
software. 
 Tubulin was run with each PCR as a housekeeping gene and used to normalize 
target gene expression within each sample. The mean value of each primer’s triplicate 
sample wells was calculated and divided by the mean value of the corresponding tubulin 
wells. Oligonucleotide sequences of primers used for qRT-PCR are listed in Table 2. 
 
2.8 Agarose Gel Electrophoresis 
 To make a 1% gel, 1g of agarose powder (Bioline; Taunton, MA) was dissolved in 
100mL of 0.5X TBE running buffer (45 mM Tris-borate, 1 mM EDTA). The solution was 
heated in a microwave at 50% power for short intervals to dissolve the agarose and avoid 
boiling the solution over to ensure the agarose concentration stayed at 1%. 0.5μL of 
ethidium bromide stain (10µg/µL) was then added to the gel before pouring the cooled 
solution into a tray with a comb. 
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Samples were prepared by adding 2.5μL 5X DNA loading buffer (0.25% bromophenol 
blue, 15% Ficoll 400) to 10μL of PCR product cDNA then loaded into individual wells. 
Hyperladder I or II molecular weight markers (BioLine; Taunton, MA) were also co-
electrophoresed with the samples, depending on the size of the amplified gene fragment. 
Gels were electrophoresed at a constant 100V for 30 minutes. To visualize bands, the gel 
was then placed on a UV transilluminator at 302nm and imaged using a CCD camera and 
software (Alpha Imager, Alpha InnoTec; Germany). 
 
2.9 Protein Isolation 
 Lysis buffer supplemented with protease inhibitors was prepared by adding 1 μL 
10mg/mL leupeptin, 1 μL 10mg/mL aprotinin, and 1μL 0.1M PMSF protease inhibitors to 
1mL lysis buffer (10mL of 1M HEPES, pH 7.5;  10mL of 0.5M EGTA, pH 8.0; 4.32 g of  
100mM β-glycerophosphate; 5mL of NP-40 lysis buffer; and 625 μL of, 2M MgCl2). Cell 
lysates were prepared by adding 100μL of lysis buffer to each well of sub-confluent cells 
grown in six-well plates after washing with cold PBS. Alternatively, 500μL of lysis buffer 
was added to sub-confluent cells grown in 10cm plates. Prior to the addition of lysis buffer, 
the plates were washed with cold PBS, which was then thoroughly aspirated. The cells 
were scraped from the plate and the solution was pipetted into microcentrifuge tubes. The 
tubes were centrifuged at 4˚C and 10,000RPM for 10 minutes to allow for pellet formation. 
The clarified protein sample supernatants were removed and kept at -20˚C. 
 To determine protein concentrations, a standard curve was prepared by making 
serial dilutions of bovine serum albumin (BSA) (Thermo Scientific HyClone Labs, Inc.; 
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Logan, UT) in water to determine the absorbance at 600nm visual light for protein 
concentrations of 50μg/mL, 25μg/mL, 10μg/mL, 5μg/mL, and 1μg/mL. The absorbance 
was plotted against the concentration and the line of best fit was calculated. This equation 
was then used to quantify protein samples. 
 After determining the protein concentration of samples, the amount of protein in 
the most dilute sample was calculated for a set volume determined by the thickness of the 
gel to be made. The volume containing the same amount of protein was calculated for all 
remaining samples and the total volume made up to the original volume. 5X SDS sample 
buffer (0.25M Tris-HCl pH6.8, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 0.5M 
DTT) was then added to each sample in microcentrifuge tubes for a final concentration of 
1X. The tubes were heated at 100˚C for 10 minutes to denature the proteins. After a quick 
chill on ice, samples were kept at -20˚C until needed. 
 
2.10 Western Blot Analysis 
To determine the amount and molecular size of proteins present in a sample, 
Western Blotting was used. Cell lysates were prepared and quantified as previously 
described and electrophoresed on a 1.5 mm thick 10%  Tris/glycine SDS-polyacrylamide 
gel containing 0.1% SDS (36) for 1.5 hours at 110V in 1X SDS-PAGE running buffer 
(20mM Tris-glycine pH 8.3, 100mM NaCl, 70mM EDTA, 2% (w/v) SDS). Proteins were 
then transferred to a PVDF transfer membrane (Immobilon-P) (Millipore Corp.; Bedford, 
MA) overnight in 1X transfer buffer (20mM Tris-HCl pH 7.9, 100mM NaCl, 70mM 
EDTA, 20% MeOH). Following transfer, the proteins were fixed by placing the membrane 
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in 100% methanol then allowing it to dry. To rehydrate the membrane, the membrane was 
placed back into 100% methanol then hydrated in TBS (10 mM Tris HCl pH 7.6, 150 mM 
NaCl) supplemented with 0.5% Tween 20 (Fisher Bioreagents; Rockville, MD) (T-TBS). 
Membranes were washed three times in T-TBS for 10 minutes each then incubated 
in blocking buffer (5% non-fat dried milk in T-TBS) for one hour on a shaker before 
incubating overnight at 4˚C in primary antibody recognizing a specific target protein 
diluted in blocking buffer (Table 3). Membranes were then washed as before in T-TBS and 
bound antibody was detected by 1 hour incubation at room temperature with the 
appropriate horseradish peroxidase-conjugated (HRP) secondary antibody diluted in 
blocking buffer (Table 3). The interaction of primary and secondary antibodies was 
detected using a mixture of equal parts Western Lightning Oxidizing Reagent Plus and 
Western Lightning Enhanced Luminol Reagent Plus (PerkinElmer Life Sciences Inc.; 
Billerica, MA) and imaged using Blue X-ray film (Phenix Research Products; Candler, 
NC) with a Kodak X-OMAT 2000 Processor. 
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Primary Antibody Raised Against Dilution Secondary Antibody 
p53 (DO-1): sc-126 aa 11-25 1:1,000 Anti-mouse 
p53 (FL-393): sc-6243 aa 1-393 1:1000 Anti-rabbit 
p63 (4A4): sc-8431 
aa 1-205 
(ΔN C-terminus) 
1:250 Anti-mouse 
EPS8 aa 628-821 1:5,000 Anti-mouse 
Actin (I-19): sc-1616 C-terminus 1:1,000 Anti-goat 
Table 3. Antibodies for Western Blot. All were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) except EPS8, which was obtained from BD 
Biosciences (San Jose, CA). 
 
2.11 Immunoprecipitation 
 Cell lysates were first prepared and quantified as described above. 1mg of each 
sample was placed into a microcentrifuge tube and the volume was adjusted to 1mL with 
cold lysis buffer. To this, 1μg of antibody per 1mg of the target protein was added and the 
tubes were placed in a rotator at 4˚C overnight. 30μL of  Protein G PLUS-Agarose 
Immunoprecipitation Reagent (sc-2002; Santa Crus Biotechnology, Inc.; Santa Cruz, CA) 
was then added to each tube, mixing between each to ensure the packed bead volume was 
15μL for all samples. Samples were again placed in a rotator at 4˚C for 50 minutes. The 
tubes were then centrifuged at 4˚C and 10,000RPM for 10 minutes to collect the beads. 
The supernatant was quickly poured off and the samples were washed three times with 
1mL of cold lysis buffer. Between each wash, the contents of each tube was mixed and 
centrifuged for 1 minute at 4˚C and 10,000RPM. After the third wash, the lysis buffer was 
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quickly poured off and samples were again centrifuged for 1 minute. The residual lysis 
buffer was then carefully removed using a pipette. 
 To prepare samples for Western Blot, 15μL of lysis buffer was added to the beads 
to bring the volume back to 30μL for each sample. 6μL of 5X SDS sample buffer was then 
added to each tube, resulting in a dilution to 1X. Samples were heated at 100˚C for 10 
minutes to release the protein from the antibody in addition to denaturing the proteins as 
previously described. For each immunoprecipitated sample, a corresponding whole-cell 
sample was also prepared as mentioned in section 2.8 to be included in the Western Blot 
analysis. After a brief chill on ice, samples were kept at -20˚C until needed. 
 
2.12 Cell Treatment with EGF 
 Duplicate samples were plated into six-well plates and allowed to attach overnight. 
The cells were then incubated overnight in 3 mL of 1% serum supplemented with sodium-
pyruvate and penicillin-streptomycin as previously described. Epidermal growth factor 
(EGF) (BD Biosciences; Bedford, MA) was diluted 1:10 in complete growth medium then 
added to one of each duplicate sample wells to yield a final dilution of 1:1000. The other 
well was used as a control with no EGF. The plates were incubated for 48 hours and RNA 
was isolated to be analyzed by QRT-PCR as previously described. 
 
2.13 Wound-Healing (Scratch) Assay 
 To measure cell motility, the migration of cells into the space of a “wound” 
administered into a confluent cell monolayer was measured. Cells were plated in triplicate 
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into 12-well plates and cultured to 100% confluence. One scratch per well was then 
administered to the center of each well using a sterile pipette tip to create a wound in the 
monolayer, and the width of the scratch was measured under a 5x objective using a light 
microscope and AxioVision software (Carl Zeiss Microimaging Inc.; Thornwood, NY). 
After incubation for 7 hours, the wound width was measured again at the same position. 
These data were used to calculate the average rate of migration as µm traveled per hour. 
 
2.14 Proliferation Assays 
 In order to establish cell proliferation rate, cells were first trypsinized and counted 
as previously described then cells were plated in quadruplicate, at a density of 5x10
3
 cells 
per well of a 24-well plate. Samples were cultured for seven days and the media was 
changed every other day. On the final day, 100μL of MTT reagent (5 mg/mL thiazolyl 
Blue tetrazolium bromide, 98%, in PBS) (Alpha Aesar; Ward Hill, MA) was added to the 
media and the plates were incubated overnight to allow for crystal formation. The media 
was then carefully aspirated and 1mL of solublization buffer (10% SDS in 0.01M HCl) 
was added to each well and the plates were again incubated overnight. A 
spectrophotometer was used to determine the absorbance of each well using visible light at 
570nm, using solublization buffer to blank. Mean absorbance was then calculated for each 
quadruplicate sample. 
 Alternatively, on day 7 the cells were detached in 50μL of trypsin then resuspended 
in 100μL media to make a total volume of 150μL. Cells were counted as previously 
described and the mean cell number was calculated for each sample. 
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2.15 Attachment Assay 
 The attachment efficiency of cells subjected to biological assays was assessed by 
crystal violet staining (protocol modified from (37)). Cells were seeded in triplicate at a 
density of 1 x 10
5
 cells per well of a 12-well plate and incubated for 1 hour as previously 
described. The media was removed and cells washed once with PBS, incubated in 0.1% 
crystal violet in PBS for 5 minutes, and washed 4 times in PBS. 1 mL of 70% ethanol was 
added to each well to dissolve the stain and absorbance readings were taken at 600nm 
using a spectrophotometer. 70% ethanol was used as a blank reading. The mean 
absorbance was then calculated for each sample. 
 
2.16 Collection of Conditioned Media 
 Cells were seeded in duplicate at a density of 1 x 10
4
 cells per well of a 12-well 
plate and allowed to attach for 24 hours. Cells were then washed with PBS and incubated 
in serum-free media for 48 hours as previously described. The media was collected and 
pooled for each sample set and stored at -20˚C. Total cell counts from each well were also 
determined as previously described and the average cell number calculated for each 
sample. 
 
2.17 Enzyme-Linked Immunosorbent Assay (ELISA) 
 To measure the levels of secreted CXCL5 protein, conditioned media was assayed 
using the DuoSet ELISA Development System (R&D Systems; Minneapolis, MN) and the 
manufacturer’s instructions. 100 μL of CXCL5 capture antibody was added to each well of 
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a flat-bottom 96-well plate and the sealed plates were incubated overnight at room 
temperature. The plates were washed four times with 400 μL of Wash Buffer (PBS 
supplemented with 0.05% Tween 20) (PBS-T) then inverted and blotted against clean 
paper towels until the wells were completely dry. Plates were blocked using 300 μL of 
Reagent Diluent (1% BSA in PBS) per well for 1 hour at room temperature then the wash 
step was repeated as before, ensuring the liquid is completely removed from the plates. 100 
μL of conditioned media samples or corresponding dilutions in reagent diluent were added 
to triplicate wells along with standards and appropriate blanks or controls, sealed, then 
incubated for 2 hours at room temperature. Standards were prepared by performing serial 
dilutions of CXCL5 standard, starting at 1:2000 and continuing to 1:7.1825. Reagent 
diluent was used as a blank and serum-free media was used as a negative control.  
 The wash step was then repeated as previously mentioned before adding 100 μL of 
Detection Antibody to each well, sealing the plates as before, and incubating for another 2 
hours at room temperature. The plates were again washed and 100 μL of Streptavidin-HRP 
was added to each well. The plates were sealed and incubated for 20 minutes at room 
temperature. Additionally, the plates were covered with aluminum foil to reduce exposure 
to light. After a final wash step, 100 μL of Substrate Solution (1:1 mixture of Color 
Reagent A (H2O2) and Color Reagent B (Tetramethylbenzidine)) was added to each well. 
Plates were sealed and covered as in the previous step, and incubated for 20 minutes at 
room temperature. 50 μL of Stop Solution (2N H2SO4) was then added to each well to stop 
the reaction, turning the solution from blue to yellow. 
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Optical density was measured at 450nm immediately using a microplate 
spectrophotometer (Epoch; BioTek Instruments; Winooski, VT) and Gen5 software. 
CXCL5 concentration was calculated from the standard curve. The average was calculated 
for each sample and normalized to the number of cells per well in each sample as 
previously measured to determine the amount of CXCL5 secreted per cell. 
 
2.19 Statistical Analysis 
 Data were analyzed by unpaired t-test to compare two means using GraphPad 
QuickCalcs software (http://www.graphpad.com/quickcalcs). A p-value less than 0.05 was 
considered statistically significant.  
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Results 
 
 
 
3.1 HN12 Cells Express Low Levels of p63 
It has been previously shown that primary and metastatic tumor cells derived from 
the same patient have distinctly different levels of chemokine expression (18) and that the 
transcription factor p63 may contribute to this difference by inhibiting CXCL5 (W.A. 
Yeudall, unpublished data), so we first wanted to determine the expression level of p63 in 
our model system. We isolated RNA from HN4 and HN12 cells, reverse transcribed it, 
then analyzed the cDNA product by qRT-PCR and normalized the results to tubulin as an 
internal standard. As Figure 8 shows, HN12 cells show a significantly lower level of p63 
mRNA expression compared to HN4 cells, which is consistent with published data. 
 
3.2 High CXCL5 Expression in HN12 Cells 
We also wanted to confirm the level of CXCL5 expression in our model system, so 
qRT-PCR was performed using primers specific for CXCL5. As shown in Figure 9, HN12 
cells show significantly higher CXCL5 mRNA expression compared to that of HN4 cells, 
which is consistent with published data (18). Higher expression of CXCL5 observed in 
HN12 cells coupled with the lower p63 expression raises the possibility of a negative 
correlation between these two molecules. 
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Figure 8. HN12 cells show lower expression of p63 mRNA. 
Expression of p63 mRNA in HN4 and HN12 cells as measured by qRT-PCR, 
normalized to tubulin as a standard. Data are representative of at least three 
independent experiments. (Bar = S.E.M.) 
 
 
Figure 9. HN12 cells show higher expression of CXCL5 mRNA.  
Expression of CXCL5 mRNA in HN4 and HN12 cells as measured by qRT-
PCR, normalized to tubulin as a standard. Data are representative of at least 
three independent experiments. (Bar = S.E.M.) 
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3.3 Inhibition of p63 Enhances CXCL5 Expression 
To next test the hypothesis that p63 inhibits CXCL5 expression, we nucleofected 
HN4 cells with either small interfering RNA (siRNA) against p63 or with luciferase 
siRNA as a control. RNA was isolated then cDNA was prepared and analyzed by qRT-
PCR. As Figure 10A shows, transfection with p63 siRNA results in inhibition of p63 
mRNA expression compared to the control and Figure 10B shows that this inhibition of 
p63 results in elevated CXCL5 mRNA expression compared to the control. Together with 
the data showing HN12 cells express low levels of p63 and high levels of CXCL5, these 
data support the hypothesis that p63 is a negative regulator of CXCL5 expression. 
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Figure 10. Inhibition of p63 causes an increase in CXCL5 expression.   
(A) Expression of p63 mRNA and (B) and CXCL5 mRNA for HN4 cells 
transfected with either p63 siRNA or luciferase siRNA control, normalized to 
tubulin as a standard. Data are representative of at least three independent 
experiments. (Bar = S.E.M.) 
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3.4 HN4/H179L Cells Express Gain-of-Function Mutant p53 
Previous data have shown that gain-of-function (GOF) mutant p53 increases 
CXCL5 expression in lung cancer cells (20), and that mutant p53 can interact with p63 
(24), which our data suggests may be an inhibitor of CXCL5. Because of this, we next 
wanted to test the contribution of p63 to the mechanism of mutant p53 regulation of 
CXCL5 expression. HN4 cells were chosen for this model system because they express 
low levels of CXCL5 and high levels of p63 and we hypothesize that mutant p53 will 
inhibit the p63 repression of CXCL5 to cause an increase in expression of this chemokine.  
We nucleofected HN4 cells with a plasmid encoding the H179L gain-of-function 
mutant p53, which has a leucine substitution at codon 179, together with neomycin 
resistance and a plasmid containing the coding sequence for mCherry.  As shown in Figure 
11, individual G418-resistant clones were selected based on fluorescence intensity as 
visualized under a fluorescent microscope. Isolated clones were expected to express the 
target H179L plasmid in addition to the other two selection plasmids. A separate HN4 
transfection was also completed with a plasmid containing an empty G418-resistant 
plasmid as a control. 
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Figure 11. Individual HN4/H179L clones selected for high fluorescence. 
HN4 cells transfected with a plasmid encoding H179L mutant p53 were also 
transfected with a plasmid encoding mCherry. HN4/v and HN4 are shown as a 
control. (5x magnification.) 
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To determine whether the cells successfully incorporated the H179L plasmid and 
express mutant p53, cell lysates were prepared and protein expression levels were analyzed 
by Western Blot. As Figure 12 shows, there are clear p53 bands in the H179L lanes, while 
these bands are absent in the vector control lanes. The actin bands are shown as an internal 
control for equal loading across all samples, indicating the observed differences are due to 
a difference in protein expression and not caused by a change in sample loading. The 
relative densities were measured, normalized to actin, and are shown below the Western 
Blot results. 
 
3.5 Mutant p53 Leads to an Increase in CXCL5 Expression 
Next, we wanted to determine the effect of mutant p53 on CXCL5 expression, so 
qRT-PCR was performed and the results are shown in Figure 13. There is a significant 
increase in CXCL5 mRNA expression in the HN4 cells expressing mutant p53 compared 
to the empty vector control. This result supports the hypothesis that mutant p53 causes an 
increase CXCL5 expression, which is consistent with what has been previously found with 
similar experiments in lung cancer cells (20). 
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Figure 12. Mutant p53 is expressed in HN4 cells transfected with H179L. 
p53 protein expression levels were measured for HN4/H179L and vector 
control clones (top). Actin levels were measured as a control (middle). Relative 
densities of the p53 bands normalized to actin are also shown (bottom). 
 
 
Figure 13. Elevated CXCL5 mRNA expression with mutant p53. 
Average expression of CXCL5 mRNA for three individual G418-Selected 
HN4 clones as measured by qRT-PCR, normalized to tubulin as a standard. 
An empty vector HN4 transfectant is used as a control. Data are representative 
of at least three independent experiments. (Bar = S.E.M.) 
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To complement this observation, conditioned media were collected from each 
sample of cells seeded at the same density and the level of CXCL5 protein secreted by the 
cells was measured using an enzyme-linked immunosorbent assay (ELISA) as described in 
Methods. The results in Figure 14 show that there is a significant increase in the secretion 
of CXCL5 by the HN4 cells expressing mutant p53 compared to the vector control, which 
is not unexpected given the similar increase observed for CXCL5 mRNA expression. 
 
3.6 Mutant p53 Does Not Alter p63 mRNA Expression 
Next, we wanted to determine what effect, if any, mutant p53 has on p63, so we 
first tested p63 mRNA levels using qRT-PCR. The results in Figure 15 show that there is 
not a statistically significant difference in p63 expression between the H179L transfectants 
and the empty vector control, which indicates mutant p53 does not alter p63 mRNA 
expression. This result is not unexpected because the presence of mutant p53 has been 
suggested to alter p63 protein activity
 
(24), not p63 mRNA production. 
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Figure 14. Increased CXCL5 protein secretion with mutant p53.  
CXCL5 protein expression in two individual G418-selected HN4 clones 
expressing mutant p53 as measured by ELISA, normalized to the number of 
cells per sample. An empty vector HN4 transfectant was used as a control. 
Data are representative of two independent experiments. (Bar = S.E.M.) 
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Figure 15. Mutant p53 does not alter expression of p63 mRNA.  
Average expression of p63 mRNA for three individual G418-Selected HN4 
clones as measured by qRT-PCR, normalized to tubulin as a standard. An 
empty vector HN4 transfectant was used as a control. Data are representative 
of at least three independent experiments. (Bar = S.E.M.) 
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Because p63 mRNA expression levels in the mutant p53 expressing cells are 
similar to the levels observed for the vector control, any observed changes in CXCL5 
expression could be due to the presence of mutant p53. There is also the possibility that 
mutant p53 is acting to decrease p63 protein levels to cause the observed increase in 
CXCL5 expression. This is suggested by data shown in Figures 16 and 17, in which the 
p63 bands for the HN4/H179L cells expressing mutant p53 show reduced density 
compared to that of the vector control. 
 
3.7 Gain-of-Function Mutant p53 Binds p63 
Thus far, we have provided evidence that p63 may be a negative regulator of 
CXCL5 expression and that inhibition of p63 correlates with increased levels of CXCL5. 
We have also shown that HN4 cells expressing mutant p53 express elevated levels of 
CXCL5 compared to the vector control and reduced levels of p63 protein. These two 
observations taken together suggest that the mechanism by which mutant p53 causes an 
increase in CXCL5 expression is through interaction with p63 protein, resulting in p63 
inhibition. 
To assess the interaction between mutant p53 and p63, we immunoprecipitated cell 
lysates using antibodies specific for p63 as described in Methods, then analyzed the 
products by Western Blot. Whole-cell lysates were also electrophoresed as a comparison. 
As shown in Figure 16, p63 bands are visible for the p63 immunoprecipitated samples, 
indicating successful immunoprecipitation of the target protein. These lanes also show 
bands when probed for p53, but these 53kD bands overlap the 50kD immunoglobulin 
   
 46 
heavy chain bands so these observations are based on the relative densities shown below 
the Western Blot results. The p53 plus heavy chain bands have increased density compared 
to the HN4 empty vector control cells that does not express mutant p53 as shown 
previously in Figure 12 and by the corresponding whole cell lysate lane in Figure 16. We 
expect that the density of this band must then correspond to the heavy chain alone. 
We were able to isolate both p53 and p63 when immunoprecipitating for p63, 
which suggests these proteins are associated in the cells. Actin and IgG light chain bands 
are shown as an internal control for equal loading across the whole cell lysate and 
immunoprecipitated samples, respectively. This indicates that the observed band densities 
are due to differences in protein expression levels, not due to error in sample loading. 
Together, these data suggest that mutant p53 protein interacts directly with p63 to 
cause an alteration in the normal function of p63. It is proposed that it is through this 
interaction that mutant p53 prevents p63-induced reduction in CXCL5 expression and that 
it actually causes an increase in chemokine expression. 
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Figure 16. p53 is bound to p63 in HN4 cells transfected with H179L. 
Cell lysates were immunoprecipitated with p63-specific antibodies. Whole 
cell lysate samples are shown as a comparison. Actin and immunoglobulin 
light chain levels are shown as a control. Relative densities of the p63 and p53 
bands normalized to actin for whole cell lysates, or normalized to light chain 
for IPs are also shown. 
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3.8 Inhibition of p63 Enhances CXCL5 Expression in the Presence of Mutant p53 
So far our data suggest that the mechanism by which mutant p53 increases CXCL5 
expression in our model system is through inhibition of p63, so we next wanted to 
determine what effect inhibition of p63 would have on CXCL5 expression in these cells. 
We nucleofected our model system cells with either p63 siRNA or luciferase siRNA as a 
control, then confirmed downregulation of p63 protein expression by p63 siRNA by 
preparing cell lysates and analyzing them by Western Blot. As Figure 17A&B show, cells 
transfected with p63siRNA do not express detectable p63, whereas p63 bands are observed 
in the control luciferase siRNA transfectant lanes. This indicates that the siRNA 
successfully interfered with expression of the p63 gene, both for the cells expressing 
mutant p53 and the empty vector control cells. 
Our previous data showed that inhibition of p63 in the parental HN4 cells results in 
enhanced CXCL5 expression, so we next wanted to determine the effect of p63 inhibition 
on CXCL5 expression in the presence of mutant p53. We hypothesized that mutant p53 
acts by interfering with the p63 repression of CXCL5 expression, so we would expect 
further inhibition of p63 to cause an even higher increase in CXCL5. As the results in 
Figure 18 show, for both the mutant p53-expressing HN4 cells and the vector control, 
inhibition of p63 results in an increase in CXCL5 expression compared to the luciferase 
siRNA control, which is consistent with our previous results implicating p63 as a negative 
regulator of CXCL5. Additionally, the increase in CXCL5 expression in the HN4/v/p63 
siRNA cells in response to p63 inhibition is significantly higher than that observed in the 
HN4/H179L/luc siRNA control cells, almost reaching the expression levels of HN4/H179L 
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cells with p63 inhibited. This may suggest that mutant p53-mediated inhibition of p63 
function is inefficient compared to siRNA-mediated downregulation, or that mutant p53 
elevates chemokine expression by two (or more) mechanisms: one dependent on p63 and 
one independent. These two observations together suggest that inhibition of p63 alone may 
be sufficient to cause an increase in CXCL5 expression, which points to p63 as a crucial 
mediator in the mechanism of p53 regulation of this chemokine. 
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Figure 17. Successful inhibition of p63 expression with p63 siRNA. 
p63 expression in HN4 cells expressing mutant p53 and the vector control 
transfected with either p63 or luciferase siRNA (top). Actin levels were 
measured as a control (middle). Relative densities of the p63 bands 
normalized to actin are also shown (bottom). (A) and (B) correspond to two 
separate siRNA transfection experiments. 
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Figure 18. Inhibition of p63 causes an increase in CXCL5 expression.  
Expression of CXCL5 mRNA for mutant p53 expressing HN4 cells transfected 
with either p63 siRNA or luciferase siRNA control, normalized to tubulin as a 
standard. Empty vector control is shown as a comparison. Data are 
representative of at least three independent experiments. (Bar = S.E.M.) 
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3.9 Mutant p53 Increases Proliferation and Motility 
To determine the significance of the CXCL5 mRNA and protein expression data 
obtained thus far, biological experiments were performed because mutant p53 has also 
been linked to cell migration and proliferation in cancer (18, 20). Additionally, reduced 
p63 expression has been linked to increased tumor cell invasion and metastasis (25) and 
our cells expressing mutant p53 also show reduced levels of p63 expression.  
First, to determine the effect of mutant p53 on cell motility, a wound-closure 
(scratch) assay was performed. The cells were plated in triplicate into 12-well plates and 
grown to 100% confluence, a “wound” was made with a pipette tip, and the width of the 
denuded region was measured at 0h then 7h, as shown in Figure 19. These data were used 
to calculate the rate of migration and the results are shown in Figure 20. Cells transfected 
with mutant p53 show a significant increase in migration rate compared to that of the 
vector control cells, which is consistent with published data (20). 
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Figure 19. “Scratch” width measured at 0h and again at 7h. 
HN4/v and HN4/H179L cells were subjected to wound closure assay, as 
described in the Methods. Migration rate was calculated by dividing the 
distance migrated by the time. Data were obtained by 12 independent 
measurements, and are representative of at least three independent 
experiments. (5x magnification.) 
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Figure 20. Enhanced cell migration with mutant p53. 
Average distance traveled as measured by the Scratch Assay. An empty vector 
HN4 transfectant is used as a control for the HN4H179L transfectants. Data 
are representative of at least three independent experiments. (Bar = S.E.M.) 
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 CXCL5 has also been shown to enhance cell proliferation (18), so to test this in the 
presence of mutant p53, cells were seeded at 5x10
3
 cells per well in quadruplicate in 24-
well plates and cultured for seven days. At that point, either an MTT assay was performed 
by first adding MTT reagent to crystalize the cells overnight then dissolving the crystals in 
solublization buffer to measure the absorbance, or the cells were counted. The results are 
shown in Figure 21. For both assays, the cells expressing mutant p53 show a significant 
increase in proliferation compared to the empty vector control. Again, this supports the 
hypothesis that mutant p53 enhances cell proliferation. 
To confirm that these results showing the HN4 cells expressing mutant p53 have 
increased proliferative capacity are due to the increase in CXCL5 and not to an acquired 
advantage that allows for increased plating efficiency, an attachment assay was performed. 
As the results in Figure 22 show, the cells expressing mutant p53 do not have a significant 
attachment advantage, but there is still a 1.8-fold increase in cell attachment with the 
HN4/H179L cells compared to the vector control. This suggests that the increase in 
proliferation observed in the HN4 cells expressing mutant p53 is due to increased cell 
growth rates but the increased plating efficiency cannot be completely ruled out as a 
contributing factor. 
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Figure 21. Increased proliferation with mutant p53. 
Average absorbance as measured by (A) MTT Assay or (B) average number 
of cells per well, after 7 days. Cells were seeded at a density of 5x10
3
 
cells/mL. An empty vector HN4 transfectant is used as a control. Data are 
representative of at least three independent experiments. (Bar = S.E.M.) 
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Figure 22. No attachment advantage with mutant p53.  
Average absorbance as measured by crystal violet attachment assay as 
described in Methods, after 1 hour. Cells were seeded at a density of 1x10
3
 
cells/well. An empty vector HN4 transfectant is used as a control. Data are 
representative of at least three independent experiments. (Bar = S.E.M.) 
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3.10 HN4/H179L Cells Display Increased CXCL5 Expression in Response to EGF 
Previous studies have shown that another mechanism by which CXCL5 expression 
is increased in tumor cells is through stimulation of epidermal growth factor receptor 
(EGFR) signaling (3). We hypothesized that mutant p53 cooperates with this EGF pathway 
to further increase chemokine expression so to test this in our cells expressing mutant p53, 
we treated cells with EGF. RNA was isolated for reverse transcription and the cDNA 
product was analyzed by qRT-PCR with primers specific for CXCL5. Cells were grown in 
1% serum media alone as a control.  
As the results in Figure 23 show, cells expressing mutant p53 show a statistically 
significant increase in CXCL5 mRNA expression when treated with EGF compared to the 
no EGF control, which still shows higher CXCL5 expression than the vector control cells 
with and without EGF treatment. This result is expected if mutant p53 and EGF act via 
independent pathways to increase CXCL5 expression in a cooperative manner. 
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Figure 23. Cooperative increase in CXCL5 with mutant p53 plus EGF. 
Expression of CXCL5 mRNA in G418-selected HN4 clones in the presence 
and absence of EGF treatment as measured by qRT-PCR, normalized to 
tubulin as a standard. An empty vector HN4 transfectant as used as a control. 
Data are representative of at least three independent experiments. (Bar = 
S.E.M.) 
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3.11 HN4/EPS8/H179L Cells Express Both Mutant p53 and EPS8 
Our data thus far suggests that mutant p53 cooperates with the EGFR pathway to 
increase CXCL5 mRNA expression, so we next wanted to evaluate the role of the 
downstream EGFR pathway mediator, EPS8 (15), in this regulation. Previously transfected 
HN4 cells that overexpress EPS8 and possess puromycin-resistance were transfected with 
a plasmid containing the gene encoding for the H179L p53 mutant plus G418-resistance 
and mCherry. As a control, HN4/H179L cells were transfected with an empty vector 
encoding the gene for puromycin resistance and HN4/EPS8 cells were transfected with an 
empty vector encoding the G418-resistance gene. These cells were grown in media 
containing both G418 and puromycin to select only for the cells that express both of these 
antibiotic resistance plasmids. Figure 24 shows phase-contrast microscope images. 
To assess whether the HN4/EPS8 cells successfully incorporated the mutant p53 
plasmid, cell lysates were prepared and analyzed by Western Blot and the results are 
shown in Figure 25. Actin bands are shown as an internal control for equal loading across 
all samples and the relative densities are also shown, normalized to actin. The 
HN4/EPS8/H179L cells show bands for both p53 and EPS8, indicating successful co-
expression of these two plasmids, but the expression levels of each are lower than would 
be expected given the band densities of the controls. The EPS8 band is half as dense when 
co-expressed with mutant p53 compared to the HN4/EPS8/v control and the p53 band 
shows a similar reduction in density compared to that of the HN4/H179L/v control. 
Interestingly, the HN4 cells expressing the mutant p53 plasmid alone have increased EPS8 
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expression compared to the HN4 empty vector control, raising the possibility that mutant 
p53 increases EPS8 expression. 
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Figure 24. HN4 cells co-transfected with H179L and EPS8. 
HN4 cells expressing EPS8 were transfected with a plasmid encoding H179L 
mutant p53. HN4/EPS8/v and HN4/H179L/v are shown as a control. (5x 
magnification.) 
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Figure 25. HN4/EPS8/H179L cells express both mutant p53 and EPS8. 
EPS8 protein expression levels were measured for HN4/v, HN4/EPS8/v, 
HN4/H179L/v, and HN4/EPS8/H179L cells (top). Actin levels were measured 
as a control (middle). Relative densities of the bands normalized to actin are 
also shown (bottom). 
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3.12 Mutant p53 and EPS8 Cooperate to Increase CXCL5 Expression 
 Next, we wanted to determine what effect co-expression of EPS8 and mutant p53 
would have on the expression levels of CXCL5 mRNA, so we performed qRT-PCR and 
the results are shown in Figure 26. HN4 cells overexpressing EPS8 show an increase in 
CXCL5 that is consistent with published data (35) and the HN4 cells co-expressing mutant 
p53 and EPS8 show CXCL5 expression that is slightly higher than with EPS8 alone. The 
HN4 cells expressing the H179L mutant p53 plasmid and show a resulting increase in 
EPS8 expression show the highest expression of CXCL5 mRNA. These data taken 
together suggest that mutant p53 and EPS8 may function in a cooperative manner to 
increase expression of CXCL5. 
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Figure 26. EPS8 and mutant p53 cooperate to increase CXCL5. 
Average expression of CXCL5 mRNA in selected G418-/puromycin-selected 
HN4 cells as measured by qRT-PCR, normalized to tubulin as a standard. 
Empty vector HN4/H179L and HN4/EPS8 transfectants were used as a control. 
Data are representative of at least three independent experiments. (Bar = 
S.E.M.) 
 
  
  66 
Discussion 
 
 
4.1 Mutant p53 Enhances HNSCC Tumorigenesis 
Previous studies have shown that gain-of-function (GOF) mutant p53 increases 
expression of the CXC-chemokine, CXCL5 (20), which has been linked to increased tumor 
cell motility and proliferation (18). Mutant p53 has also been shown to favor tumorigenesis 
through enhancement of tumor cell migration and proliferation (20), but the exact 
mechanisms have yet to be fully understood. Several possible mechanisms have been 
postulated through which mutant p53 can increase CXCL5 expression, including inhibition 
of its family member, p63 (24), direct binding of the CXCL5 promoter region to activate 
gene expression (20), or mutant p53 activation of NF-κB2 (20) or other transcription 
factors yet to be identified. Thus far, mutant p53 has not been localized on the CXCL5 
promoter using ChIP assays. As others have suggested that some mutant p53 gain-of-
function activity is mediated by interfering with p63 function (24), in this study we 
investigated whether GOF mutant p53 enhances expression of CXCL5 by interfering with 
p63 function in oral cancer cells. 
 In the current study, we utilized HN4 tongue primary tumor cells transfected with 
the H179L gain-of-function mutant p53 as a model system to study the effect of mutant 
p53 on CXCL5 expression. After confirming mutant p53 expression by Western Blot, we 
showed an 11-fold increase in CXCL5 expression using both qRT-PCR and ELISA in the 
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HN4 cells expressing mutant p53 compared to the empty vector control. We were able to 
induce significantly higher levels of CXCL5 expression by expressing mutant p53 in HN4 
cells that normally express very low levels of this chemokine, as shown by both transcript 
levels and amount of secreted protein. 
We were also able to show that when HN4 cells express mutant p53, these cells 
respond with an almost 2-fold increase in cell migration, as measured by wound closure 
assays. Because of the increased levels of chemokines secreted by the HN4/H179L cells, 
this increase in migration could be due to the more concentrated chemokine gradient 
created by these cells. The cells would then be attracted toward the gradient at a faster rate 
than for the control cells that are not exposed to this same gradient and normally show low 
levels of migration. It is also possible that the mechanism is not via CXCL5-induced 
motility, and further experiments using inhibition of the CXCR2 receptor or downstream 
mediators could be utilized to confirm the role of this chemokine in cell migration. 
Additionally, proliferation assays showed mutant p53 caused up to a 3-fold 
increase in cell growth. HN4 cells normally proliferate slowly and we were able to 
demonstrate that expression of mutant p53 in these cells induces an increase in this 
biological process that is important for tumor progression. We also performed attachment 
assays, which suggest that when HN4 cells express mutant p53 they may have an 
advantage that allows for increased attachment efficiency when plating, although the 
results were not statistically significant. Further studies should be completed to determine 
whether this attachment advantage is only observed when plating, or if this acquired 
phenotype plays a role with tumor progression to possibly favor colonization of a 
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secondary tumor site during metastasis. Additional experiments are also needed to 
determine whether the observed increase in cell proliferation by HN4 cells expressing 
mutant p53 is the result of increased CXCL5 expression, or if there is another mechanism 
that is responsible. 
The results of these studies are significant because they confirm previous lung 
cancer studies that show it only takes a single missense mutation in the p53 protein to 
induce a more metastatic phenotype (21). This is even more concerning because of the 
increased risk for p53 mutations associated with tobacco use (6) and the low five-year 
survival rate associated with metastasized tumors (3). Figure 27 shows the possible 
interactions between these molecules to induce the altered biological responses observed.  
Although we did not explore this in the current study, it would be interesting to also 
compare the results of HN4 cells expressing mutant p53 with HN12 cells derived from a 
metastasized lymph node tumor. 
 
Figure 27. Mutant p53 promotes HNSCC tumorigenesis. 
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4.2 p63 is a Negative Regulator of CXCL5 Expression Inhibited by mp53 
Preliminary studies from our laboratory have suggested that inhibition of p63 
correlates with an increase in CXCL5 expression in lung cancer cells. In the present study, 
we found a profound increase in CXCL5 expression in HN4 oral cancer cells transfected 
with p63 siRNA. This raises the possibility that p63 inhibition may be a contributory event 
to tumor progression that is common across different types of cancers. Additionally, we 
were able to show a similar upregulation of CXCL5 with siRNA inhibition of p63 in HN4 
cells expressing mutant p53. These cells already showed elevated levels of CXCL5 
expression and using siRNA against p63, we were able to elevate it further. 
HN4/H179L showed lower p63 protein levels but no significant change in p63 
mRNA, which suggests this decrease is not transcriptionally mediated. It may instead be 
possible that mutant p53 leads to increased turnover of the p63 protein, although this has 
not been reported previously. Decreasing p63 mRNA further using siRNA may be 
responsible for the enhanced levels of CXCL5 over and above those seen in the presence 
of mutant p53. Alternatively, it may be that mutant p53 activates CXCL5 expression by 
mechanisms other than (or in addition to) p63 inhibition. Also, the CXCL5 expression in 
the HN4/H179L cells transfected with p63 siRNA or luciferase control siRNA are still 
significantly higher than the corresponding HN4/v cells. This also suggests there may be 
an additional p63-independent mechanism by which mutant p53 increases CXCL5 
expression because regardless of the p63 status, the mutant p53-expressing cells express 
higher CXCL5. 
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Previous studies have shown that p53 interacts with p63 to inhibit its function (24), 
so we sought to investigate this p63-dependent regulation of CXCL5 expression further. 
Our results suggest two possible ways through which mutant p53 inhibits p63, which are 
illustrated in Figure 28. One possibility is that mutant p53 causes a decrease in p63 protein, 
which reduces the inhibition on CXCL5 enough to cause the increase in CXCL5 
expression but it is also likely that this is mediated by direct protein interaction. By binding 
p63, mutant p53 could inhibit the function of p63 as a transcriptional repressor of CXCL5. 
When immunoprecipitating p63, we were able to co-precipitate p53 as well, which 
suggests that these proteins are bound in the cells. Together with the decreased levels of 
p63 measured in the HN4 cells expressing mutant p53, this adds evidence to suggest that 
mutant p53 binding p63 may have two effects: one to one to decrease the total p63 protein 
levels by targeting the molecule for degradation and another to inhibit p63 via direct 
binding. This two-fold inhibition of p63 protein expression and function could together 
result in the observed increase in CXCL5 expression in our model system. 
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Figure 28. Two possible p63-dependent mechanisms of mutant p53 
regulation of CXCL5 expression. 
 
In addition to our HN4/H179L mutant p53 model system, we also investigated 
CXCL5 expression with upregulation of p63 in HN12 cells and these results are shown in 
Appendix A. HN12 cells normally express low levels of p63 and high levels of CXCL5 
(18), so our expectation was that by increasing p63 levels in these cells there would be a 
corresponding decrease in CXCL5 expression. Unfortunately, we were unsuccessful in 
elevating the levels of p63 in these cells, but the unexpected result was that following 
transfection, these cells actually showed a decrease in p63 expression with a corresponding 
increase in CXCL5 expression compared to the empty vector control. This result also 
supports the hypothesis that p63 acts to inhibit the expression of CXCL5. Previous studies 
have shown that overexpressing p63 may result in growth arrest and apoptosis (7), which 
may offer an explanation as to why this approach was not successful. If the cells that 
successfully incorporated the p63 plasmid underwent apoptosis, that could leave a 
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surviving population that only express lower levels of p63. This could account for our 
observed decrease in p63 expression and corresponding CXCL5 increase. 
 
4.3 Mutant p53 and EGFR Signaling Cooperate to Elevate CXCL5 
 Previous studies have also implicated EGFR-dependent signaling pathways as 
another mechanism by which CXCL5 is increased in cancer, possibly through the 
downstream regulator, EPS8 (35). Previous data have shown that treatment of cells with 
EGF stimulates CXCL5 expression along with other genes that favor metastasis (3) and it 
was also found that overexpression of EPS8 causes an increase in CXCL5 expression (35). 
We hypothesized that mutant p53 cooperates with the EGFR signaling pathway to 
further increase the expression of CXCL5. When treating HN4 cells expressing mutant p53 
with EGF, we were able to show a 3.5-fold increase in CXCL5 expression compared to 
cells with no EGF treatment, while the vector control HN4 cells showed a less pronounced 
change in CXCL5 expression. Our data have shown that mutant p53 expression alone acts 
to elevate the expression of CXCL5 in our model system, and upon activation of the EGFR 
signaling pathway with EGF ligand, the expression of CXCL5 is elevated further. If 
mutant p53 and EGFR act through the same pathway to activate CXCL5 expression, we 
would not expect to see this increase in CXCL5 expression, so this suggests that these 
pathways act through independent mechanisms to cooperatively increase the expression of 
CXCL5. 
We have already demonstrated a link between mutant p53 and p63, and there are 
previous data that also link p63 and EGFR. These studies show that treatment with EGF 
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causes decreased p63 expression, but also shows an increase in ΔNp63α-induced motility 
(10, 34). This seems to be conflicting evidence, but there are several possible explanations. 
It could be the fact that these results come from studies performed with different cell types, 
and p63 expression levels may be cell type-specific. Another possible explanation is that 
reduction of total p63 levels could allow for a more profound effect of one specific 
isoform. The decrease in p63 could be caused by a reduction in only some isoforms, while 
others could still be upregulated while maintaining the same level of total p63. Further 
studies should be completed with our model system to determine the expression levels of 
the individual p63 isoforms in our model system to more specifically identify the role that 
p63 plays in tumor progression. 
Taken together with our data showing upregulation of CXCL5 expression in cells 
expressing mutant p53 when treated with EGF, these studies suggest that inhibition of p63 
may also play a role in this increase. By further inhibiting p63 expression to alleviate 
repression of CXCL5 in our cells, EGFR signaling pathways may be promoting elevation 
in CXCL5 expression. Another possibility is that expression of the EGFR is upregulated 
by mutant p53. If the cells express more of the receptor, the effect of treatment with EGF 
ligand would be more pronounced in the HN4/H179L cells than in the HN4/v control cells. 
This is consistent with our observations so in addition to further experiments to evaluate 
p63 levels, effects on EGFR expression should also be determined. 
We next sought to show a similar effect by co-transfecting HN4 cells with EPS8 
and mutant p53. We were able to successfully transfect both expression plasmids into HN4 
cells; however, this resulted in lower levels of expression as compared to the single 
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transfectants, which was unexpected. Interestingly, when testing for EPS8 using Western 
Blot, we noticed an elevation in the expression levels of EPS8 in the HN4/H179L/v cells, 
compared to the HN4 control. This was not expected given the EPS8 levels expressed by 
the HN4/v cells, and raises the possibility that mutant p53 may also regulate EPS8. This 
could be yet another mechanism by which mutant p53 elevates CXCL5 expression in these 
cells. To further test this, the levels of EPS8 expression for our individual HN4/H179L 
clones could be measured to determine whether these cells also express detectable EPS8. 
When we measured CXCL5 expression levels, HN4 cells expressing EPS8 showed 
an increase in CXCL5 that we would expect given published data (15), and the HN4 cells 
expressing mutant p53 showed CXCL5 elevation similar to the data we observed in our 
previous results. We were unable to show a synergistic increase in CXCL5 expression in 
our co-transfectant model, but this does not necessarily mean that these two pathways act 
independently. Table 4 shows the relative expression of EPS8, mutant p53, and CXCL5 in 
this model system. The HN4 cells expressing both mutant p53 and EPS8 showed 
approximately half of the mutant p53 expression than the HN4/H179L/v, while both 
express similar levels of EPS8. These EPS8 levels, however, are approximately half that of 
the HN4/EPS8/v cells, which showed the lowest increase in CXCL5 expression. The 
HN4/EPS8/H179L cells showed a slightly higher level of CXCL5 despite showing half the 
EPS8 expression of HN4/EPS8/v. The slight increase in CXCL5 expression could be due 
to the presence of mutant p53, which raises the possibility that if these cells expressed 
higher EPS8 or mutant p53, they would also express higher levels of CXCL5. This is 
actually shown by the HN4/H179L/v cells, which was unexpected. These cells express 
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similar levels of EPS8 as the HN4/EPS8/H179L cells, but express almost double the level 
of mutant p53, which correlates to a little over 2-fold increase in CXCL5 expression.  
 
 HN4/v HN4/EPS8/v HN4/H179L/v HN4/EPS8/H179L 
EPS8 --- 1.0 0.6 0.5 
p53 --- --- 1.0 0.6 
CXCL5 0.1 1.0 3.2 1.4 
Table 4. Relative Expression of EPS8, p53, and CXCL5. 
 
 Together with our findings with EGF treatment, these data also suggest a 
cooperative function between these two pathways. These results are significant because 
like mutant p53, EGFR is also overexpressed in many cancers (15), and this pathway has 
been shown to favor tumor progression (33). If these two pathways that independently 
promote tumorigenesis actually work together to amplify the expression of CXCL5, they 
could reduce the time it takes for a tumor to progress and metastasize to distant sites in the 
body. Additional studies could be done to further determine the degree to which 
cooperativity occurs and confirm whether the EPS8 downstream mediator plays a role. For 
example, the effect on CXCL5 expression could be evaluated in response to inhibition of 
EPS8 using siRNA. Alternatively, the levels of the EPS8 downstream mediator, FOXM1 
(35), could also be measured in our model system. Most importantly, the effect of this 
cooperativity on the biological processes important for tumor progression should be 
evaluated. 
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4.4 Limitations of the Current Study 
 Although our in vitro model has offered an effective way to study HNSCC, there 
are still limitations that should be taken into consideration. Because these cells are grown 
in culture, they are not exposed to all of the different factors that are present in the body. 
We do try to mimic body conditions by controlling the temperature and humidity of the 
environment in which our cells are grown, and by supplementing the cell culture media 
with growth factors, but the current study should be continued to an in vivo model to 
complement the results we have obtained thus far. 
 Another assay we utilized was the wound closure, or scratch, assay. Although this 
is an effective way to measure the migration rates of cells in culture, it is a two-
dimensional model and an additional study would be to repeat the experiment using a 
trans-well migration assay to measure motility through a three-dimensional matrix. This 
would be more representative of what actually occurs in the body. Another limitation to the 
wound closure assay is that the width of the initial scratch might influence migration rate 
because of the CXCL5 gradient produced by the cells. This could also affect the migration 
rates, especially for the cells expressing mutant p53 that secrete elevated levels of this 
protein. This experiment was repeated multiple times and the results were averaged to 
reduce any effect this might have had on the calculated migration rates. 
 We were able to utilize MTT and cell counting assays to test the proliferative 
capacity of our cells; however there are some disadvantages to these methods. Both MTT 
and cell counting assays depend on plating the correct initial densities of cells for all 
samples, so even slight differences in the starting concentration may affect the final result. 
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Plating the cells at a higher initial density could give the cells a growth advantage which 
could be interpreted as increased proliferation. Another limitation to the cell counting 
assay is that by using a Cellometer and cell counting program, there is the possibility that 
concentrations could be incorrectly measured. If the cells were not properly resuspended 
and separated, a grouping of cells could be counted as only one which would result in 
inaccurate concentration results. Also, the presence of dead cells on the slide could 
contribute to altered concentration that could skew the results. To avoid this, we were 
careful to properly resuspend cells and to limit the time between trypsinization and cell 
counting to avoid cell death. 
 
4.5 Future Studies 
 The future direction of this line of study should ultimately continue to animal in 
vivo studies, but additional in vitro experiments could also be done. To further complement 
the migration data we have obtained thus far, invasion assays could also be performed to 
determine whether mutant p53 induces a more invasive phenotype in our model system. 
Luciferase assays and chromatin immunoprecipitation (ChIP) assays could also be 
completed to determine the effect of mutant p53 or EGFR inhibition of p63 on the CXCL5 
promoter. Luciferase assays could be used to determine the activity of the promoter and 
ChIP assay would show whether the promoter is in an active form or if p63 is bound.  
The goal of further in vitro experimentation should be to elucidate the mechanism by 
which mutant p53, p63, and EGFR signaling function to regulate the expression of 
CXCL5; and what impact this has on tumor progression. Finally, the role of individual p63 
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isoforms in the overall function of p63 in our model system should be tested to determine 
what isoforms contribute to the tumorigenic phenotype.  
 
4.6 Conclusions 
The results of the current study indicate a role for mutant p53 in head and neck 
squamous cell carcinoma proliferation, migration, and tumorigenicity, possibly through 
enhancement of CXCL5 expression. The results support the hypothesis that GOF mutant 
p53 enhances expression of CXCL5 by interfering with p63 function in oral cancer cells, 
and that mutant p53 cooperates with EGFR/EPS8 signaling to further deregulate 
chemokine expression. Figure 29 shows the possible interactions between these molecules 
that result in increased expression of CXCL5 and altered biological responses. Further 
research can be conducted to determine the extent of the role played by p63 in mutant p53 
regulation of CXCL5 in tumorigenicity and the extent of the cooperativity between EGFR 
signaling and mutant p53. 
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Figure 29. Possible interactions between mutant p53, p63, and EGFR. 
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APPENDIX A 
 
Reduced p63 Expression in HN12 Cells Transfected with ΔNp63α 
We have shown that inhibiting p63, whether by siRNA or through mutant p53 
interference, results in an increase in CXCL5 expression, so we wanted to explore this 
further. HN12 cells expressing low levels of p63 and high levels of CXCL5 were 
nucleofected with both a plasmid containing the ΔNp63α isoform plus G418-resistance and 
mCherry. We selected individual clones grown in G418-supplemented media based on the 
intensity of fluorescence fluorescence as visualized under a fluorescent microscope, shown 
in Figure 30. As with our previous clone selections, the assumption was that if the cells 
incorporated the mCherry plasmid, they also incorporated the ΔNp63α plasmid. A separate 
transfection was completed with a plasmid containing an empty G418-resistant plasmid as 
a control. 
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Figure 30. Individual HN12/ΔNp63α clones selected for high fluorescence. 
HN12 cells transfected with a plasmid encoding ΔNp63α were also 
transfected with a plasmid encoding mCherry. Colonies were selected for high 
fluorescence. HN12/v and HN12 are shown as a control. 
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To determine whether the HN12/ΔNp63α transfections were successful in 
upregulating p63 expression, protein lysates were prepared and analyzed by Western Blot. 
As Figure 31 shows, the p63 band is stronger in the empty vector control lane than in the 
lane for HN12/ΔNp63α. Actin bands are shown as an internal control and the relative 
densities are shown below the Western Blot results. This was not the expected result, so 
p63 mRNA levels were also measured using qRT-PCR and the results shown are an 
average for four separate clones. As Figure 32 shows, p63 mRNA expression levels are 
reduced in the ΔNp63α transfectants compared to the vector control, which is consistent 
with the Western Blot results. Together, these data show that there is an unexplained 
downregulation of p63 by the HN12 cells upon transfecction of the ΔNp63α isoforms. 
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Figure 31. Reduced p63 protein expression in HN12/ΔNp63α cells. 
p63 protein expression levels were measured for HN12/ΔNp63α and vector 
control clones (top). Actin levels were measured as a control (middle). Relative 
densities of the p53 bands normalized to actin are also shown (bottom). 
 
 
Figure 32. Reduced p63 mRNA expression in HN12/ΔNp63α cells. 
Expression of p63 mRNA in four separate G418-selected HN12 clones as 
measured by qRT-PCR, normalized to tubulin as a standard. An empty vector 
HN12 transfectant was used as a control. Data are representative of at least 
three independent experiments. (Bar = S.E.M.) 
   
 92 
Increased CXCL5 with Reduced p63 Expression 
 Although the HN12/ΔNp63α transfections did not yield desired overexpression of 
p63, we still wanted to evaluate the effect on CXCL5 expression given that the results have 
so far show that a decrease in p63 expression causes an increase in CXCL5. In order to test 
this, qRT-PCR was completed with primers specific for CXCL5. As Figure 33 shows, there 
is a significant increase in CXCL5 expression in the HN12/ΔNp63α cells compared to the 
empty vector control, which is consistent with our previous findings. A similar increase 
was observed for CXCL5 protein secretion, as measured by ELISA, and these results are 
shown in Figure 34. Although the observed increase in CXCL5 expression in the cells 
showing decreased p63 expression supports the hypothesis that p63 is involved with 
repression of CXCL5, our ultimate goal was to overexpress p63 and because we were 
unsuccessful no further experiments were done using this approach. 
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Figure 33. Reduced p63 correlates with elevated CXCL5 mRNA. 
Average expression of CXCL5 mRNA for four individual G418-selected 
HN12 clones as measured by qRT-PCR, normalized to tubulin as a standard. 
An empty vector HN12 transfectant  was used as a control. Data are 
representative of at least three independent experiments. (Bar = S.E.M.) 
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Figure 34. Reduced p63 correlates with elevated CXCL5 protein. 
CXCL5 protein expression in two individual G418-selected HN12 clones 
expressing ΔNp63α as measured by ELISA, normalized to the number of cells 
per sample. An empty vector HN12 transfectant was used as a control. Data are 
representative of two independent experiments. (Bar = S.E.M.) 
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